循環器ジャーナル66巻2号

2018年04月発行

特集 Structural Heart Diseaseインターベンション—「新しい」インターベンションのすべて Ⅰ．TAVI

TAVI後CTと至適抗血栓療法

著者： 柳澤亮¹

所属機関： ¹慶應義塾大学医学部循環器内科

ページ範囲：P.210 - P.213

Point
・TAVI後の4DCTにより検出される無症候性血栓症が問題視され，TAVI後レジメンの見直しの必要性といった大きな問題に波及している．
・至適抗血栓療法を模索するべく無作為化比較対照試験や観察研究が現在多く進行している．

参考文献

1) Mylotte D, Andalib A, Theriault-Lauzier P, et al:Transcatheter heart valve failure:a systematic review. Eur Heart J 36:1306-1327, 2015

2) Latib A, Naganuma T, Abdel-Wahab M, et al:Treatment and clinical outcomes of transcatheter heart valve thrombosis. Circ Cardiovasc Interv 8, 2015

3) Makkar RR, Fontana G, Jilaihawi H, et al:Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves. N Engl J Med 373:2015-2024, 2015

4) Pache G, Schoechlin S, Blanke P, et al:Early hypo-attenuated leaflet thickening in balloon-expandable transcatheter aortic heart valves. Eur Heart J 37:2263-2271, 2016

5) Hansson NC, Grove EL, Andersen HR, et al:Transcatheter Aortic Valve Thrombosis:Incidence, Predisposing Factors, and Clinical Implications. J Am Coll Cardiol 68:2059-2069, 2016

6) Yanagisawa R, Hayashida K, Yamada Y, et al:Incidence, Predictors, and Mid-Term Outcomes of Possible Leaflet Thrombosis After TAVR. JACC Cardiovasc Imaging, 2016［Epub ahead of print］

7) De Marchena E, Mesa J, Pomenti S, et al:Thrombus formation following transcatheter aortic valve replacement. JACC Cardiovasc Interv 8:728-739, 2015

8) Leon MB, Smith CR, Mack MJ, et al:Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med 374:1609-1620, 2016

9) Jose J, Sulimov DS, El-Mawardy M, et al:Clinical Bioprosthetic Heart Valve Thrombosis After Transcatheter Aortic Valve Replacement:Incidence, Characteristics, and Treatment Outcomes. JACC Cardiovasc Interv 10:686-697, 2017

10) Chakravarty T, Sondergaard L, Friedman J, et al:Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves:an observational study. Lancet 389:2383-2392, 2017